Unique pore architecture underlies constitutive gating of human retinalTRPM1

This study presents the first cryo-EM structure of human TRPM1 in a conducting state, revealing an unexpected clockwise domain-swapped pore architecture with a wide intracellular gate that explains its constitutive activity and provides a structural basis for understanding congenital night blindness.

The Gist

The Big Picture: Fixing the "Night Vision" Switch

Imagine your eyes are a high-tech security camera system. When it gets dark, the system needs a special switch to turn on the "night vision" mode. In humans, this switch is a tiny protein machine called TRPM1.

If this switch is broken, you get a condition called Congenital Stationary Night Blindness. You can see fine in the day, but when the lights go out, you are completely blind. For a long time, scientists knew this protein was important, but they didn't know what it actually looked like or how it worked. It was like trying to fix a car engine without ever seeing the blueprint.

This paper is the first time scientists have taken a high-resolution 3D photo (using a super-powerful microscope called Cryo-EM) of the human TRPM1 switch. And what they found was a complete surprise.

---

The Surprise: The "Backwards" Door

Most protein channels in our body that let electricity flow (like gates for ions) are built like a standard door. They have a handle (the sensor) and a door (the pore). Usually, if you look at these doors from the outside, the handle and the door are twisted in a counter-clockwise direction. It's like a standard screw thread; you know exactly how it's supposed to turn.

The TRPM1 discovery:
The scientists found that the TRPM1 switch is built backwards.

• The Analogy: Imagine a standard door where the hinges are on the left. Now, imagine a door where the hinges are on the right, but the handle is still on the left. It's a mirror image of everything else.
• The Science: The TRPM1 channel has a "clockwise" twist. The part that senses the signal and the part that opens the gate are swapped in a direction opposite to almost every other known channel in the human body. It's a unique architectural design that nature invented just for this specific job.

Why Does This Matter? The "Always-On" Light

Because of this weird, backwards twist, the TRPM1 switch behaves differently than its cousins.

• The Normal Behavior: Most channels are like a light switch that is OFF until you flip it. They stay closed until a specific signal (like a hormone or a change in voltage) tells them to open.
• The TRPM1 Behavior: Because of its unique "clockwise" structure, the TRPM1 switch is constantly ON. It's like a light bulb that is wired to stay on all the time.
  • In the Eye: This is actually perfect for night vision. In the dark, your eye's "ON" cells need to be constantly active to tell your brain, "It's dark, keep the vision going!" The TRPM1 channel stays open by default, keeping the signal flowing.
  • The Problem: If you want to turn it off (when you see light), the body has to use a special "brake" (a signaling molecule) to force the door shut. If the door is broken or the brake fails, the system gets confused, leading to blindness.

The "Key" and the "Lock"

The scientists also tested what happens when they poke the channel with different chemicals (drugs).

• They found that TRPM1 is sensitive to a specific drug called 2-APB, which acts like a key that jams the door shut.
• Interestingly, its close relative, TRPM3, is immune to this drug. This proves that even though they look similar, their "backwards" architecture makes them react to the world in totally different ways.

The "Broken Blueprint" (Disease Connection)

The paper also looked at the blueprints of people who have night blindness. They found that the mutations (typos in the genetic code) causing the disease are often located right at the "hinges" or the "twist" of the channel.

• The Analogy: If you have a door with a weird twist, and someone breaks the hinge or snaps the handle, the door won't work.
• The Result: These mutations prevent the channel from assembling correctly or stop it from staying open, effectively breaking the night vision switch.

Summary: What Did They Learn?

1. First Look: They finally saw the human TRPM1 channel in 3D.
2. Unique Design: It has a "clockwise" twist that no other human channel has.
3. Always Open: This unique shape makes the channel naturally want to stay open (constitutively active), which is exactly what the eye needs for night vision.
4. Medical Hope: Now that we have the blueprint, doctors and drug developers can see exactly where the "typos" are that cause blindness. This opens the door to designing new medicines that can fix the hinge or the lock, potentially curing night blindness in the future.

In short: Scientists found a biological door that opens the wrong way, which turns out to be the perfect design for seeing in the dark. Now that we know how it's built, we can finally fix it when it breaks.

Technical Summary

1. Problem Statement

Transient Receptor Potential Melastatin 1 (TRPM1) is a calcium-permeable, non-selective cation channel critical for retinal ON-bipolar cell signaling and night vision. Loss-of-function mutations in TRPM1 cause congenital stationary night blindness (CSNB). Despite its physiological importance, TRPM1 has remained structurally and functionally poorly characterized due to:

• Expression Challenges: The protein is predominantly retained in the endoplasmic reticulum (ER) when expressed in heterologous systems, hindering functional assays.
• Structural Unknowns: No high-resolution structure existed to explain its unique gating mechanism (tonically active in darkness, suppressed by mGluR6 signaling) or its quaternary organization. Previous studies suggested a dimeric assembly, conflicting with the canonical tetrameric nature of TRP channels.
• Mechanistic Gap: The structural basis for its constitutive activity and how it differs from closely related family members (like TRPM3) was unknown.

2. Methodology

The authors employed a multidisciplinary approach combining protein engineering, electrophysiology, and cryo-electron microscopy (cryo-EM):

• Protein Engineering & Expression:
  • To overcome ER retention and improve stability, they engineered a truncated construct (TRPM1-EM) lacking exon 11 (a flexible poly-lysine loop) and disordered C-terminal residues.
  • The protein was expressed in HEK293F cells using a BacMam system and purified via Strep-tag affinity chromatography and Size-Exclusion Chromatography (SEC).
• Functional Characterization:
  • Single-Channel Recordings: Purified wild-type (WT) and TRPM1-EM were reconstituted into planar lipid bilayers to measure spontaneous activity, conductance, and voltage dependence in the absence of agonists.
  • Cellular Assays: Fura-2 AM calcium flux assays were performed to test agonist responses (pregnenolone sulfate, clotrimazole, voriconazole) and pharmacological inhibition (2-APB).
• Cryo-EM Structure Determination:
  • TRPM1-EM was vitrified and imaged on a Titan Krios microscope (300 kV).
  • Data processing involved motion correction, CTF estimation, particle picking (TOPAZ), and 3D reconstruction using CryoSPARC and RELION, achieving a global resolution of 4.36 Å.
  • Atomic models were built and refined against the density map, utilizing AlphaFold predictions as a starting guide for intracellular domains.

3. Key Contributions & Results

A. Functional Validation of Constitutive Gating

• Constitutive Activity: Single-channel recordings revealed that TRPM1 is constitutively active in the absence of ligands, with a high open probability ($P_o \approx 0.7$) and a conductance of ~12 pS.
• Pharmacology: The channel is potentiated by pregnenolone sulfate (PS) and PIP₂ but is distinctively inhibited by 2-APB, differentiating it from the 2-APB-insensitive TRPM3.
• Construct Validity: The TRPM1-EM construct retained the functional properties of the wild-type channel (constitutive activity, agonist potentiation) but showed improved membrane trafficking, validating it as a structural surrogate.

B. Structural Discovery: A Novel "Clockwise" Domain-Swapped Architecture

The most significant finding is the discovery of a non-canonical transmembrane topology:

• Clockwise Pore Swapping: While most 6-transmembrane (6-TM) tetrameric channels (e.g., K⁺, Na⁺, Ca²⁺ channels, and other TRPMs) exhibit a counter-clockwise domain-swapped arrangement of the pore module (S5-P-S6) relative to the voltage-sensor-like domain (VSLD, S1-S4), TRPM1 adopts a clockwise rotation.
• Magnitude of Rotation: The pore module is rotated approximately 53° clockwise relative to the VSLD compared to TRPM3. This involves substantial translational shifts (~51–56 Å) and internal remodeling of the S5 and S6 helices.
• Stabilization: This inverted topology is stabilized by a unique network of hydrophobic interactions distinct from TRPM3.

C. Structural Basis for Constitutive Gating

The structure captures TRPM1 in a fully open, conductive state:

• Selectivity Filter: The filter (formed by G1056 and E1052) is markedly dilated (8.35 Å radius) compared to the closed state of TRPM3 (3.65 Å), allowing hydrated cations to pass.
• Intracellular Gate: The S6 bundle crossing is fully splayed open (~8.5 Å diameter), lined by residues N1116 and I1111.
• Pore Helix Orientation: The C-terminal end of the pore helix is repositioned closer to the extracellular leaflet and adopts a membrane-parallel orientation, creating a wide hydrophobic cavity that stabilizes permeating ions.
• Intracellular Coupling: The MHR3/4 domains engage the pre-S1 elbow of neighboring subunits (via D702/D703 and Y727/T766 interactions), a signature of open states in other TRP channels, further stabilizing the conductive conformation.

4. Significance

• Paradigm Shift in Ion Channel Architecture: This study overturns the prevailing view that all 6-TM tetrameric channels share a counter-clockwise pore orientation. It demonstrates that a clockwise domain-swapped fold is a viable alternative architecture for ion conduction.
• Mechanism of Constitutive Activity: The structure provides a direct mechanistic explanation for TRPM1's unique physiology: the intrinsic clockwise rotation and resulting pore dilation bias the channel toward an open state, consistent with its role as a tonically active channel in retinal ON-bipolar cells.
• Disease Relevance: The structural map allows for the precise localization of disease-associated mutations (causing CSNB) to subunit interfaces and gating hotspots, offering a framework for understanding how specific mutations disrupt folding, assembly, or gating.
• Therapeutic Potential: By defining the unique pharmacological profile (e.g., 2-APB sensitivity) and structural features distinct from TRPM3, this work lays the groundwork for designing specific modulators for TRPM1-related visual and pigmentary disorders.

In summary, this paper resolves the long-standing structural mystery of TRPM1, revealing a unique clockwise pore architecture that underpins its constitutive gating and providing a critical foundation for understanding retinal signaling and congenital night blindness.